These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 8977495

  • 1. Isolation of human adenovirus type 5 variants resistant to the antiviral cidofovir.
    Gordon YJ, Araullo-Cruz TP, Johnson YF, Romanowski EG, Kinchington PR.
    Invest Ophthalmol Vis Sci; 1996 Dec; 37(13):2774-8. PubMed ID: 8977495
    [Abstract] [Full Text] [Related]

  • 2. The antiviral resistance and replication of cidofovir-resistant adenovirus variants in the New Zealand White rabbit ocular model.
    Romanowski EG, Gordon YJ, Araullo-Cruz T, Yates KA, Kinchington PR.
    Invest Ophthalmol Vis Sci; 2001 Jul; 42(8):1812-5. PubMed ID: 11431446
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Efficacy of topical cidofovir on multiple adenoviral serotypes in the New Zealand rabbit ocular model.
    Romanowski EG, Gordon YJ.
    Invest Ophthalmol Vis Sci; 2000 Feb; 41(2):460-3. PubMed ID: 10670476
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Evaluation of Cidofovir (HPMPC, GS-504) against adenovirus type 5 infection in vitro and in a New Zealand rabbit ocular model.
    de Oliveira CB, Stevenson D, LaBree L, McDonnell PJ, Trousdale MD.
    Antiviral Res; 1996 Jul; 31(3):165-72. PubMed ID: 8811201
    [Abstract] [Full Text] [Related]

  • 8. Antiviral prophylaxis with twice daily topical cidofovir protects against challenge in the adenovirus type 5/New Zealand rabbit ocular model.
    Romanowski EG, Yates KA, Gordon YJ.
    Antiviral Res; 2001 Dec; 52(3):275-80. PubMed ID: 11675144
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Inhibitory effect of (S)-HPMPC, (S)-HPMPA, and 2'-nor-cyclic GMP on clinical ocular adenoviral isolates is serotype-dependent in vitro.
    Gordon YJ, Romanowski E, Araullo-Cruz T, Seaberg L, Erzurum S, Tolman R, De Clercq E.
    Antiviral Res; 1991 Jul; 16(1):11-6. PubMed ID: 1776874
    [Abstract] [Full Text] [Related]

  • 11. Therapeutic potential of Cidofovir (HPMPC, Vistide) for the treatment of DNA virus (i.e. herpes-, papova-, pox- and adenovirus) infections.
    De Clercq E.
    Verh K Acad Geneeskd Belg; 1996 Jul; 58(1):19-47; discussion 47-9. PubMed ID: 8701600
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. In vitro susceptibility of adenovirus to antiviral drugs is species-dependent.
    Morfin F, Dupuis-Girod S, Mundweiler S, Falcon D, Carrington D, Sedlacek P, Bierings M, Cetkovsky P, Kroes AC, van Tol MJ, Thouvenot D.
    Antivir Ther; 2005 Jul; 10(2):225-9. PubMed ID: 15865216
    [Abstract] [Full Text] [Related]

  • 14. The in vitro and in vivo evaluation of ddC as a topical antiviral for ocular adenovirus infections.
    Romanowski EG, Yates KA, Gordon YJ.
    Invest Ophthalmol Vis Sci; 2009 Nov; 50(11):5295-9. PubMed ID: 19516011
    [Abstract] [Full Text] [Related]

  • 15. N-chlorotaurine is an effective antiviral agent against adenovirus in vitro and in the Ad5/NZW rabbit ocular model.
    Romanowski EG, Yates KA, Teuchner B, Nagl M, Irschick EU, Gordon YJ.
    Invest Ophthalmol Vis Sci; 2006 May; 47(5):2021-6. PubMed ID: 16639011
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Pretreatment of the host cell with 1-(S)-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) is sufficient for its antiviral effect.
    Otová B, Votruba I, Holý A.
    Acta Virol; 1992 May; 36(3):313-9. PubMed ID: 1360759
    [Abstract] [Full Text] [Related]

  • 18. [Antiviral effect of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine on adenovirus].
    Nakajima H, Goto M, Shimada Y, Nagamoto Y, Ishiko H, Inagawa W, Itoh N, Uchio E, Ohno S, Aoki K.
    Nippon Ganka Gakkai Zasshi; 2000 Feb; 104(2):77-81. PubMed ID: 10714154
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Efficacy of topical immunoglobulins against experimental adenoviral ocular infection.
    Nwanegbo EC, Romanowski EG, Gordon YJ, Gambotto A.
    Invest Ophthalmol Vis Sci; 2007 Sep; 48(9):4171-6. PubMed ID: 17724203
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.